Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial

Table 1

Baseline characteristics of patients with acute ischemic stroke receiving simvastatin therapy.

Characteristic	Simvastatin 10 mg (N = 34)	Simvastatin 40 mg (N = 31)	value
	Mean ± SD	Mean ± SD
Age (years)	65.09 ± 13.93	62.4 ± 15.79	0.48
Female, n (%)	17 (50)	14 (45)	0.69
SBP (mmHg)	159.79 ± 28.78	147.19 ± 25.07	0.58
DBP (mmHg)	86 ± 16.92	83.84 ± 14.38	0.23
Blood Sugar (mg/dl)	109.8 ± 27.2	113.8 ± 21.70	0.51
Cholesterol (mg/dl)	182.15 ± 35.82	194.1 ± 44.49	0.24
Triglyceride (mg/dl)	101.38 ± 67.52	133.71 ± 103.69	0.14
HDL-c (mg/dl)	46.65 ± 10.68	49.16 ± 10.92	0.35
LDL-c (mg/dl)	120.38 ± 35.68	113.81 ± 21.70	0.73
NIHSS	6.47 ± 4.90	6.61 ± 3.79	0.89
rtPA therapy
IV rtPA, n (%)	4 (11.76)	8 (25.8)	0.15
Medical history, n (%)
Ischemic stroke	2 (5)	2 (6)	0.92
Atrial fibrillation or flutter	6 (17)	3 (9)	0.35
Valvular heart disease	1 (3)	0 (0)	0.34
Hypertension	23 (67)	12 (38)	0.02
Diabetes mellitus	3 (8)	5 (16)	0.37
Dyslipidemia	16 (47)	12 (38)	0.50
Others	1 (3)	3 (9)	0.90

Note. Systolic blood pressure (SBP), diastolic blood pressure (DBP), recombinant tissue plasminogen activator (rtPA), and intravenous route (IV).